

13th August 2015

ASX ANNOUNCEMENT

RIGHTS ISSUE VERY STRONGLY SUPPORTED BY DIRECTORS

Directors of Analytica Limited (**Company**) are pleased with the successful outcome of the recent entitlement offering having raising over \$2.8m. These funds will be applied to our 3 priorities, building sales, validating through the clinical trial and seeking out international partnership opportunities.

The offer was very strongly supported by the directors. Directors took up entitlements of \$600k representing 21.4% of all funds received.

Dr Michael Monsour (Chairman)	\$400K
Mr Warren Brooks	\$130K
Mr Ross Mangelsdorf	\$ 63k
Mr Carl Stubbings (full entitlement taken up)	<u>\$ 7k</u>
	<u>\$600k</u>

Directors appendix 3y (change in directors holdings), attached.

The board are delighted and proud to welcome Dr Thomas Lonngren.

Dr Lonngren's European and United States knowledge and network will add support to international experience of director Carl Stubbings in developing global partnership opportunities for the PeriCoach. Partnership opportunities have gained momentum with interest being expressed following PeriCoach's entry into the United States and United Kingdom market.

Bryan Dulhunty
Company Secretary

Follow us on:



About Analytica Limited



Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. Product launches are anticipated in Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Michael Monsour
Date of last notice	18th December 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	11th August 2015
No. of securities held prior to change	Dr Michael Monsour <ul style="list-style-type: none"> • 2,606,337 Ordinary Shares MPAMM Pty Ltd • 44,667,785 Ordinary Shares MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 12,247,277 Ordinary Shares Halonna Pty Ltd < Monsour Family A/C • 54,664,451 ordinary shares MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 13,000,000 unlisted options
Class	Ordinary shares Listed Options <ul style="list-style-type: none"> • ALTO • ALTOA

Appendix 3Y
Change of Director's Interest Notice

Number acquired	50,020,000 Ordinary shares 16,666,666,ALTO 16,666,666 ALTOA
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$400,160
No. of securities held after change	<p><u>Ordinary Shares</u> Dr Michael Monsour</p> <ul style="list-style-type: none"> • 2,606,337 Ordinary Shares MPAMM Pty Ltd • 44,687,785 Ordinary Shares MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 19,747,277 Ordinary Shares Halonna Pty Ltd < Monsour Family A/C • 97,164,451 ordinary shares <u>ALTO</u> • 2,500,000 MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 14,166,666 Halonna Pty Ltd < Monsour Family A/C <p><u>ALTOA</u></p> <ul style="list-style-type: none"> • 2,500,000 MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 14,166,666 Halonna Pty Ltd < Monsour Family A/C <p><u>Unlisted options</u> MP Monsour Medical Practice Pty Ltd <Superannuation Account></p> <ul style="list-style-type: none"> • 13,000,000 unlisted options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of rights under entitlement offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-
Interest disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	-
Interest after change	-

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Warren Brooks
Date of last notice	11 November 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	W Brooks Investments Pty Ltd (B and P Super Fund) Warren Brooks is a director of W Brooks Investments Pty Ltd
Date of change	11th August 2014
No. of securities held prior to change	32,430,000 ordinary shares indirectly 8,000,000 unlisted options directly
Class	Ordinary shares Listed Options – ALTO and ALTOA
Number acquired	16,215,000 ordinary shares 5,405,000 ALTO 5,405,000 ALTOA
Number disposed	-
Value/Consideration	\$129,720 ordinary shares
No. of securities held after change	48,645,000 ordinary shares indirectly 5,405,000 ALTO 5,405,000 ALTOA 8,000,000 unlisted options directly

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of rights under entitlement offer
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-
Interest disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	-
Interest after change	-

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Mangelsdorf
Date of last notice	11th November 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Tambien Pty Ltd and Edmonmont (Mr Mangelsdorf is a director, shareholder, trustee)
Date of change	11th August 2015
No. of securities held prior to change	Ross James Mangelsdorf • 14,222 Ordinary Shares Ross Mangelsdorf & Jennifer Margaret Mangelsdorf • 14,222 Ordinary Shares Tambien Pty Ltd • 18,848,357 Ordinary Shares • 10,000,000 unlisted options • Edmonmont 2,280,004 ordinary shares
Class	ALT ordinary shares Listed options • ALTO • ALTOA
Number acquired	7,844,988 ordinary shares 2,614,995 ALTO 2,614,995 ALTOA

Appendix 3Y
Change of Director's Interest Notice

Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$62,760
No. of securities held after change	<p><u>Ordinary Shares</u> Ross James Mangelsdorf • 21,332 Ordinary Shares Ross Mangelsdorf & Jennifer Margaret Mangelsdorf • 21,332 Ordinary Shares Tambien Pty Ltd • 25,539,125 Ordinary Shares Edmonton • 3,420,004 ordinary shares</p> <p><u>ALTO</u> Ross James Mangelsdorf • 2,370 ALTO Ross Mangelsdorf & Jennifer Margaret Mangelsdorf • 2,370 ALTO Tambien Pty Ltd • 2,230,255 ALTO Edmonton • 380,000 ALTO</p> <p><u>ALTO</u> Ross James Mangelsdorf • 2,370 ALTOA Ross Mangelsdorf & Jennifer Margaret Mangelsdorf • 2,370 ALTOA Tambien Pty Ltd • 2,230,255 ALTOA Edmonton • 380,000 ALTOA</p> <p><u>Unlisted options</u> • 10,000,000 unlisted options</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of rights under entitlement offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
--------------------	---

Appendix 3Y
Change of Director's Interest Notice

Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
Interest acquired	-
Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Name of entity: Analytica Ltd	
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Carl Stubbings
Date of last notice	11th November 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Cumberland Pty Ltd <C&K STUBBINGS S/F A/C – an entity controlled by Carl Stubbings
Date of change	11 th August 2015
No. of securities held prior to change	1,830,882
Class	Ordinary Listed Options <ul style="list-style-type: none"> • ALTO • ALTOA
Number acquired	915,440 ordinary shares 305,146 ALTO 305,146 ALTOA
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$7,324

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	2,746,322 ordinary shares 305,146 ALTO 305,146 ALTOA
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of rights under entitlement offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a